Trans Catheter Aortic Valve Replacement
|
|
- Abigail Merritt
- 5 years ago
- Views:
Transcription
1 Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care
2 No financial conflict of interest related to this talk Will discuss some non FD approved devices
3 Review the clinical course of severe symptomatic aortic stenosis Identify treatment options for severe symptomatic aortic stenosis Review clinical trial data regarding TAVR Discuss future developments in TAVR
4
5 5 Aortic stenosis is estimated to be prevalent in up to 7% of the population over the age of Million People in US Over the Age of 65 2 It is more likely to affect men than women; 80% of adults with symptomatic aortic stenosis are male 3 Percentage Diagnosed with Aortic Stenosis
6 More Common Age-Related Calcific Aortic Stenosis Aortic stenosis in patients over the age of 65 is usually caused by calcific (calcium) deposits associated with aging Rheumatic Fever Adults who have had rheumatic fever may also be at risk for aortic stenosis Congenital Abnormality In some cases adults may develop aortic stenosis resulting from a congenital abnormality Less Common
7 3 Major Etiologies for aortic stenosis
8 Shortnss of breath Syncope/ pre-syncope Angina Fatigue Dyspnea on exertion CHF A-fib related
9 Survival after onset of symptoms is 50% at 2 years and 20% at 5 years 1 Surgical intervention for severe aortic stenosis should be performed promptly once even minor symptoms occur 1
10 5-Year Survival 8 Survival, % Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Ovarian Cancer Severe Inoperable AS* *Using constant hazard ratio. Data on file, Edwards Lifesciences LLC. Analysis courtesy of Murat Tuczu, MD, Cleveland Clinic 5 year survival of breast cancer, lung cancer, prostate cancer, ovarian cancer and severe inoperable aortic stenosis
11
12
13
14 Survival, % Patient Survival Years AVR, AVR, no Sx No Symptoms AVR, Sx AVR, Symptoms No No AVR, AVR, no No SxSymptoms No AVR, No AVR, Sx Symptoms Study data demonstrate that early and late outcomes were similarly good in both symptomatic and asymptomatic patients It is important to note that among asymptomatic patients with SAS, omission of surgical treatment was the most important risk factor for late mortality
15 Aortic Valve Replacement No Aortic Valve Replacement Studies show at least 40% of patients with severe AS are not treated with an AVR
16 16 An aortic valve replacement as an alternative to traditional thoracotomy. Less invasive than traditional thoracotomy for patients considered too high risk for traditional surgery.
17
18 Edwards Sapien Valve Stainless Steel Frame More Aortic Regurg, less AV block/ppm Better for severe bulky calcification. Medtronic CoreValve Nitinol Frame-self expanding Less Aortic Regurg, More heart block/ppm
19
20
21 Patients at Extreme Surgical Risk Foundational trials tested new TAVR therapy in patients without the option for a surgical aortic valve replacement US CoreValve Pivotal Trial PARTNER 1B CoreValve, N=489, STS 10.3% SAPIEN, N=179, STS 11.2%
22 Patients at Extreme Surgical Risk 3-Year Follow-Up PARTNER showed that by 3 years, TAVR had reduced mortality by approximately 30% compared to standard medical management. 100% Similar survival results were achieved with CoreValve in the US Pivotal Trial All-Cause Mortality 80% 60% 40% 20% PARTNER B PARTNER All-Cause B Standard Rx % % % 0% Months
23
24
25 Patients at High Surgical Risk Trials randomizing high risk patients to either TAVR or SAVR soon followed US CoreValve Pivotal Trial CoreValve, N=390, STS 7.3% vs. SAVR, N=357, STS 7.5% PARTNER 1A SAPIEN, N=348, STS 11.8% vs. SAVR, N=351, STS 11.7%
26 PARTNER 1A 5-Year Follow-Up Presented at ACC 2015 PARTNER showed that ~35% of patients survived to 5 years, regardless of treatment This study provided the first confirmation that TAVR is a reasonable alternative to surgery in high risk patients 1 Mack, et al., presented at ACC 2015
27 CoreValve US Pivotal Trial 3-Year Follow-Up Presented at ACC 2016 The CoreValve Pivotal Trial was the first to show a survival advantage with TAVR compared to SAVR, with separation of the all-cause mortality curves maintained to 3 years 1 Deeb, et al., J Am Coll Cardiol 2016 Mar 22; doi: /j.jacc
28 Patients at Intermediate Surgical Risk Randomized trial data comparing TAVR to SAVR in lowerrisk patients recently became available SAPIEN XT and SAPIEN 3 CoreValve
29 Intermediate Risk PARTNER 2A SAPIEN XT The PARTNER 2A Trial showed that TAVR with SAPIEN XT was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years 1 Smith, et al., presented at ACC 2016
30 Intermediate Risk PARTNER 2A SAPIEN XT This study also generated convincing evidence that transfemoral TAVR provides an outcome advantage to intermediate risk patients In the as-treated population, TF TAVR significantly reduced all-cause mortality or disabling stroke vs. surgery (p = 0.04) 1 Smith, et al., presented at ACC 2016
31
32
33 All cause mortality 1.1% vs 4% at 30 days 7.4% vs 13.5 % at 1 yr Disabling Stroke 1% vs 4.4% at 30 days 2.3% vs 5.9 % at 1 year 75% reduction In Death and in disabling stroke
34 Low Surgical Risk Active Trials Randomizing TAVR to SAVR Currently there is significant clinical investment in applying TAVR to younger patients at low surgical risk, both in North America and in Europe Medtronic PARTNER 3 2 UK TAVI 3 Low Risk 1 NOTION-2 4 N = ~1200 N = 1228 N = 808 N = 992 Up to 80 centers Evolut R, all routes Up to 64 centers SAPIEN 3, transfemoral All UK TAVI centers All valves, all routes All Nordic countries All valves, transfemoral Industry-sponsored 10-year follow-up Industry-sponsored 10-year follow-up Publically funded 5-year follow-up Physician and industry-sponsored 5-year follow-up 1 Popma, et al., presented at TCT 2016; 2 Mack, et al., presented at TCT 2016; 3 Moat, et al., presented at TCT 2016; 4 Sondergaard, et al., presented at TCT 2016
35
36
37 EARLY TAVR TAVR in asymptomatic severe AS TAVR UNLOAD TAVR in moderate AS with CHF/ LV dysfunction
38 Foundational TAVR Devices Complications Foundational randomized trials did provoke some concern about the safety of TAVR due to the incidence of certain complications, including stroke, conduction disturbances, paravalvular leak, and vascular trauma SAPIEN CoreValve SAPIEN XT
39 Death Stroke Vascular Complications Pacemaker implantation Paravalvular regugitation Late valve dysfunction
40 Transfemoral TAVR Devices Iterative Device Design Iterative devices have been designed to mitigate complications, simplify the procedure, and improve upon current anatomic exclusions to enable the treatment of more patients Evolut R Lotus SAPIEN 3 Portico Frame Nitinol Nitinol Cobalt Chromium Nitinol ACURATE neo Nitinol PVL Managment Extended Skirt Adaptive Seal PET Fabric Skirt Pericardial cuff Pericardial skirt Annular Range mm mm mm mm mm Positioning Recapturable Recapturable -- Recapturable -- Caliber 14 Fr/ 16 Fr equiv. 18 Fr 14 Fr / 16 Fr 18 Fr / 19 Fr 18 Fr
41
42 Embrella Embolic Deflector (Edwards Lifesciences) Triguard (Keystone Heart, Herzliya Pituach, Israel)
43 Claret Montage (Claret Medical, CA)
44 Auscultation Transthoracic Echo (TTE) Cardiac Cath. Chest X-ray Electrocardiogram
45 Confirm the patient is diagnosed with severe symptomatic native aortic stenosis Confirm the patient has been independently evaluated by two cardiac surgeons and meets the indication for TAVR Evaluate the aortic valvular complex using echocardiography Evaluate the peripheral vasculature and aortic valvular complex using MDCT Evaluate the peripheral vasculature and aortic valvular complex using catheterization Note: Evaluation using CT is typically not done unless the Heart Team confirms that patient is a candidate for TAVR
46
47
48 20 cases in the last 6 months Ages 59 to 85 High STS scores/ high risk for SAVR No Death/CVA/PPM implantation No major vascular complications ( one pseudoaneurysm ) One expected ICD to remove life-vest
49
50 TAVR is the only option for extreme risk patients TAVR is an equal or better for high risk patients TAVR is an equal or better option for intermediate risk patients TAVR for low risk patients being studied
51 SAPIEN SAPIEN XT SAPIEN 3
52 Foundational TAVR Devices Complications Foundational randomized trials did provoke some concern about the safety of TAVR due to the incidence of certain complications, including stroke, conduction disturbances, paravalvular leak, and vascular trauma SAPIEN CoreValve SAPIEN XT
53 Foundational TAVR Devices Stroke 10% Weighted average (n=8,987) 4.2% 30-Day All Stroke 8% 6% 4% 2% 6.7% 4.1% 4.6% 4.3% 5.5% 4.0% 4.9% 0% Extreme Risk P 1B N=179 Extreme Risk P 2B N=276 High Risk P 1A N=348 Extreme Risk P 2B N=284 Intermediate Risk P 2A N=1,011 Extreme Risk US Pivotal N=489 High Risk US Pivotal N=390 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
54 Foundational TAVR Devices New Permanent Pacemaker Implantation 30-Day Permanent Pacemaker 30% 20% 10% 0% 3.4% Extreme Risk P 1B N= % Extreme Risk P 2B N=276 Weighted average (n=8,987) 11.3% 3.8% High Risk P 1A N= % Extreme Risk P 2B N= % Intermediate Risk P 2A N=1, % Extreme Risk US Pivotal N= % High Risk US Pivotal N=390 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
55 Foundational TAVR Devices Vascular Complications 20% 30-Day Major Vascular Complications 15% 10% 5% 16.2% 15.2% 11.0% Weighted average (n=8987) 7.7% 9.5% *Definitions vary across studies 7.9% 8.2% 5.9% 0% Extreme Risk P 1B N=179 Extreme Risk P 2B N=276 High Risk P 1A N=348 Extreme Risk P 2B N=284 Intermediate Risk P 2A N=1,011 Extreme Risk US Pivotal N=489 High Risk US Pivotal N=390 Minimum Vessel Diameter 8.0/ / / (mm) 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
56 Foundational TAVR Devices Paravalvular Leak 100% Weighted average (n=5,127) Mild 34% / Moderate-Severe 10% 30-Day Paravalvular Leak 80% 60% 40% 20% 0% 12.0% 68.0% 17.1% 12.0% 24.2% 43.0% 41.0% 37.9% 3.7% 22.5% 11.4% 41.5% 9.0% 35.7% Extreme Risk P 1B N=153 Extreme Risk P 2B N=225 High Risk P 1A N=287 Extreme Risk P 2B N=236 Intermediate Risk P 2A N=872 Extreme Risk US Pivotal N=418 High Risk US Pivotal N=356 SAPIEN SAPIEN XT CoreValve 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
57 Transfemoral TAVR Devices Iterative Device Design Iterative devices have been designed to mitigate complications, simplify the procedure, and improve upon current anatomic exclusions to enable the treatment of more patients Evolut R Lotus SAPIEN 3 Portico Frame Nitinol Nitinol Cobalt Chromium Nitinol ACURATE neo Nitinol PVL Managment Extended Skirt Adaptive Seal PET Fabric Skirt Pericardial cuff Pericardial skirt Annular Range mm mm mm mm mm Positioning Recapturable Recapturable -- Recapturable -- Caliber 14 Fr/ 16 Fr equiv. 18 Fr 14 Fr / 16 Fr 18 Fr / 19 Fr 18 Fr
58 Real-World Evidence Base New Transfemoral Valves A literature search was conducted to identify studies reporting procedural and 30-day outcomes for groups of patients treated with new valves in real-world practice The rates of paravalvular leak, new pacemaker implantation, stroke, and major vascular complications were tabulated and the weighted average was calculated for each valve type
59 Real-World Evidence Base New Transfemoral Valves 45 unique cohorts were identified through the literature search, representing over 15,000 patients treated with new valves in real-world practice SAPIEN Evolut R 5232 Lotus 1960 ACURATE Neo 1273 Portico Patients With Data Reported
60 TAVR Stroke Rates with Contemporary Devices In contemporary practice, the overall stroke rate remains around 3.5% 30-Day All Stroke 10% 8% 6% 4% 2% 3.0% 4.0% Weighted average (n=5,547) ~3.5% 1.9% 5.5% 2.7% 1.4% 4.0% 2.7% 6.8% 3.0% 0% 0.0% CE Study N=60 FORWARD Interim Analysis N=300 US IFU N=151 SAVI Registry N=1,000 CE Study N=220 1 Manoharan, et al., J Am Coll Cardiol Intv 2015; 8: ; 2 Moellman, et al., presented at PCR London Valves 2015; 3 Linke, et al., presented at PCR London Valves 2015; 4 Kodali, et al., Eur Heart J 2016; doi: /eurheartj/ehw112; 5 Vahanian, et al., presented at EuroPCR 2015; 6 Webb, et. al. J Am Coll Cardiol Intv 2015; 8: ; 7 DeMarco, et al, presented at TCT 2015; 8 Meredith, et al., presented at PCR London Valves 2015; 10 Falk, et al., presented at EuroPCR 2016 P2 S3 IR N=1,078 P2 S3 HR/ER N=583 S3 CE IR N=101 S3 CE N=150 REPRISE II N=250 RESPOND N=1,014
61 New Permanent Pacemakers Real-World Evidence The rate of new permanent pacemaker implantation is sensitive to device type The rates are typically around 15% with Evolut R and SAPIEN 3, and approximately 2x higher with the Lotus valve New Permanent Pacemaker (Weighted Averages) 35% 30% 25% 20% 15% 10% 5% 0% 30.2% 18.2% 13.4% 8.0% 6.4% Lotus Evolut R SAPIEN 3 ACURATE Neo Portico
62 Moderate / Severe Paravalvular Leak Real-World Evidence The Lotus valve virtually eliminates moderate or severe PVL Other valves have brought the rates to ~5% or less Moderate / Severe PVL Weighted Averages 7% 6% 5% 4% 3% 2% 1% 0% 6.1% 3.8% 3.5% 2.3% 0.5% Evolut R ACURATE Neo Portico SAPIEN 3 Lotus
63 Major Vascular Complications Real-World Evidence Major vascular complications have come down under 5% across all valve types 6% Major Vascular Complications (Weighted Average) 5% 4% 3% 2% 1% 4.8% 3.8% 2.4% 2.4% 0.7% 0% SAPIEN 3 (N=6,300) Portico (N=389) Lotus (N=1,960) Evolut R ACURATE Neo (N=5,232) (N=1,273)
64 Access Trends United States The preferred access site has been dynamic in the US as the regulatory landscape has changed With the introduction of Evolut R and SAPIEN 3, more than 90% of TAVRs are performed through the TF approach 100 femoral transapical transaortic other 93% % of TAVR Procedures FDA Approval (High Risk): CoreValve Sapien XT FDA Approval (High Risk): Evolut R SAPIEN Carroll, et al., presented at TCT 2016
65 % General Anesthesia Anesthesia New Valves Increased use of the transfemoral approach has facilitated a simpler procedure, shown by the decreased use of general anesthesia in favor of conscious sedation Wide variation in anesthesia mode likely reflects geographical differences and individual physician preferences 100% 80% 60% 40% 20% 0% 37.0% FORWARD (N=300) 60.2% 72.1% IMPLANTERS Registry (N=264) STS / TVT Registry (N=3,810) 17.8% RELEVANT Registry (N=225) RESPOND (N=996) 32.9% UK Registry (228) 84.5% PARTNER 2 S3 (N=1,661) Evolut R Lotus SAPIEN 3 N R 40.1% SOURCE 3 (N=1,947) Multicenter cohorts with >200 patients
66 Foundational TAVR Devices Stroke 10% Weighted average (n=8,987) 4.2% 30-Day All Stroke 8% 6% 4% 2% 6.7% 4.1% 4.6% 4.3% 5.5% 4.0% 4.9% 0% Extreme Risk P 1B N=179 Extreme Risk P 2B N=276 High Risk P 1A N=348 Extreme Risk P 2B N=284 Intermediate Risk P 2A N=1,011 Extreme Risk US Pivotal N=489 High Risk US Pivotal N=390 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
67 Foundational TAVR Devices New Permanent Pacemaker Implantation 30-Day Permanent Pacemaker 30% 20% 10% 0% 3.4% Extreme Risk P 1B N= % Extreme Risk P 2B N=276 Weighted average (n=8,987) 11.3% 3.8% High Risk P 1A N= % Extreme Risk P 2B N= % Intermediate Risk P 2A N=1, % Extreme Risk US Pivotal N= % High Risk US Pivotal N=390 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
68 Foundational TAVR Devices Vascular Complications 20% 30-Day Major Vascular Complications 15% 10% 5% 16.2% 15.2% 11.0% Weighted average (n=8987) 7.7% 9.5% *Definitions vary across studies 7.9% 8.2% 5.9% 0% Extreme Risk P 1B N=179 Extreme Risk P 2B N=276 High Risk P 1A N=348 Extreme Risk P 2B N=284 Intermediate Risk P 2A N=1,011 Extreme Risk US Pivotal N=489 High Risk US Pivotal N=390 Minimum Vessel Diameter 8.0/ / / (mm) 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
69 Foundational TAVR Devices Paravalvular Leak 100% Weighted average (n=5,127) Mild 34% / Moderate-Severe 10% 80% 60% 40% 20% 12.0% 68.0% 17.1% 12.0% 24.2% 43.0% 41.0% 37.9% 3.7% 22.5% 11.4% 41.5% 9.0% 35.7% 0% Extreme Risk P 1B N=153 Extreme Risk P 2B N=225 High Risk P 1A N=287 Extreme Risk P 2B N=236 Intermediat e Risk P 2A N=872 Extreme Risk US Pivotal N=418 High Risk US Pivotal N= Day Paravalvular Leak 1 Leon, et al., N Engl J Med 2010;363: ; 2 Webb, et al., J Am Coll Cardiol Intv 2015;8: ; 3 Smith, et al., N Engl J Med 2011;364: ; 4 Leon, et al., N Engl J Med 2016;374: ; 5 Popma, et al., J Am Coll Cardiol 2014;63: ; 6 Adams, et al., N Engl J Med 2014;370:1790-8;;
TAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationAortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD
Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece TAVI in 2018: Landscape TAVI is a Breakthrough Technology Dramatic
More informationAortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD
Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Ομάδες εργασίας, Θεσσαλονίκη 2018 TAVI in 2018: Landscape TAVI is
More informationTAVI limitations for low risk patients
TAVI limitations for low risk patients Dr. T. Modine / P. Lancellotti MD, PhD, MBA CHRU de Lille, France Potential conflicts of interest Speaker's name: Thomas Modine I have the following potential conflicts
More informationA Thoughtful Synthesis of the TAVR Landscape: What s New, What s Needed and is There a Best-in-Class?
TVT Chicago Thursday 16th of June 2016 Session 1: TAVR 2016 Highlights and Controversies A Thoughtful Synthesis of the TAVR Landscape: What s New, What s Needed and is There a Best-in-Class? Ian T. Meredith
More informationStructural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)
Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR) Kathleen Harper DO FACC FACP 87 Chief, Cardiology Section VA Maine Healthcare Kathleen.Harper@va.gov Prevalence of Aortic Stenosis
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationComplicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato
Complicanze durante TAVI Brambilla Nedy IRCCS Policlinico San Donato 0 2 4 6 9 11 14 16 22 26 31 33 37 43 52 61 69 78 87 93 106 113 121 151 171 186 201 225 267 283 294 311 349 502 515 709 1007 Number of
More informationThe Worshipful Company of Barbers. Mr. John Hunter. History of cardiac surgery. PDA ligation. Blalock-Taussig Shunt
The Worshipful Company of Barbers Puneet Dhawan M.D Assistant Health Sciences Clinical Professor David Geffen School of Medicine at UCLA Assistant Chief Division of Cardiothoracic Surgery Harbor-UCLA Medical
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationTrans Aortic Valve Replacement Update: 2016 & Beyond
Trans Aortic Valve Replacement Update: 2016 & Beyond Rajiv Jauhar, MD, FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital, Manhasset 1 DISCLOSURE POLICY Northwell
More informationRole of Embolic Protection during TAVR
Role of Embolic Protection during TAVR Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac Catheterization Laboratories Disclosure Co PI for Sentinel Trial
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationDisclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience
Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience The LGH TAVR Program James E. Harvey, MD, MSc Medical Director, Structural Heart Intervention The Heart Group of Lancaster
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More informationCurrent Evidence in TAVI patients using ACURATE and LOTUS valves
Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts
More informationTranscatheter Valve Therapies Update
Providence Heart and Vascular Institute Transcatheter Valve Therapies Update Where In The H*@# Is All This Going??? Robert Hodson MD Medical Director, Providence Valve Center October 24, 2015 DISCLOSURES
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationThe Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy
The Future of Medicine Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy FIRST PATIENT TO UNDERGO PTCA FIRST PATIENT TO UNDERGO TAVI Grüntzig
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationTAVR and Cardiac Surgeons
TAVR and Cardiac Surgeons TAVR and Cardiac Surgeons Ragheb Hasan Consultant and Clinical Lead Cardiothoracic Surgeon Manchester Royal Infirmary, Oxford Road, Manchester UK Aortic Stenosis Is A Growing
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationCurrent Controversies. Subclinical and clinical valve thrombosis
Chapter 19: Current controversies, ongoing trials, new valves, and future directions Sukhdeep S. Basra, MD, MPH, Michael J. Mack, MD The Heart Hospital Baylor Plano, Texas Transcatheter Aortic Valve Replacement
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationWhat is Aortic Stenosis?
What is Aortic Stenosis? What is Aortic Stenosis? Very simply, aortic stenosis is a build-up of calcium deposits on the valve, which causes it to narrow and reduce blood flow to the rest of your body.
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationTHE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
More informationAortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
More informationTranscatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis
Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis John Webb MD Director interventional cardiology, St Paul s Hospital McLeod Professor of
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationStrokes After TAVR Reasons for Declining Frequency
Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationAortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationTAVR in 2017 What we know? What to expect?
Journal of Geriatric Cardiology (2018) 15: 55 60 2018 JGC All rights reserved; www.jgc301.com Perspective Open Access TAVR in 2017 What we know? What to expect? Panagiota Kourkoveli 1,*, Konstantinos Spargias
More informationTranscatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
More informationtranscatheter heart valve: THV TAVI transcatheter aortic valve implantation
transcatheter heart valve: THV TAVI transcatheter aortic valve implantation Hideki OSHIMA 1. はじめに transcatheter heart valve: THV 1) transcatheter aortic valve implantation: TAVI transcatheter mitral valve
More informationEduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I. Professor of Medicine & Surgery Associate Dean for International Medicine University of
Catheter Based Treatment of Valvular Heart Disease In the Adult Sping 2016 Eduardo de Marchena, M.D., F.A.C.C., F.A.C.P., F.S.C.A.I. Professor of Medicine & Surgery Associate Dean for International Medicine
More informationTranscatheter Heart Valve Procedures
Medical Coverage Policy Transcatheter Heart Valve Procedures Table of Contents Coverage Policy... 1 Overview... 2 General Background... 2 Coding/Billing Information... 27 References... 29 Effective Date...11/15/2017
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationTranscatheter Aortic Valve Replacement with Evolut-R
Transcatheter Aortic Valve Replacement with Evolut-R Department of Transcatheter Heart Valves and 2 nd Cardiothoracic Surgery Clinic K. Spargias, M.Chrissoheris, A.Halapas, I. Nikolaou, S.Pattakos Disclosures
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationDisclosures. During the past 12 months, I have received research grants, advisory boards, consultation fees/honoraria, and/or travel expenses from:
Update on Transcatheter Aortic Valve Replacement Vinod H. Thourani, MD Associate Professor of Cardiothoracic Surgery Associate Director, Structural Heart Center Associate Director, CTS Clinical Research
More informationEmerging Transcatheter Aortic Valve Technologies
East Meets West: Emerging Transcatheter Aortic Valve Technologies Emerging valve systems and iterative technologies from around the world and how they could shape global practice going forward. BY FEDERICO
More informationDisclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation
What s New in Valvularand Structural Heart Disease Ryan C. Shelstad, MD Surgical Enthusiast, Valvular and Structural Heart Disease Bryan Heart Cardiothoracic Surgery Disclosures None relevant to the presentation
More informationAndrzej Ochala, MD Medical University of Silesia, Katowice, Poland
Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland Bicuspid aortic valve o Most common congenital heart disease in adults (1% - 2%) o AS is the most common complication of BAV o Patophysiology
More information3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong
3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease
More informationTAVI: Present and Future Perspective
TAVI: Present and Future Perspective Igor F. Palacios, M.D. Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Percutaneous transcatheter
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationThe Sentinel Dual Filter Device Design Features & EU Clinical Trial Results
The Sentinel Dual Filter Device Design Features & EU Clinical Trial Results Nicolas M. Van Mieghem, MD, PhD, FESC Director of Interventional Cardiology Thoraxcenter, Erasmus MC Rotterdam Disclosure Statement
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationTAVI Technology and Procedural Changes
TCT AP 2013 Seoul, South Korea April, 2013 TAVI Technology and Procedural Changes Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São
More informationEmbolic Protection Devices for Transcatheter Aortic Valve Replacement
Embolic Protection Devices for Transcatheter Aortic Valve Replacement James M. McCabe, MD Medical Director, Cardiac Cath Lab University of Washington Seattle, WA Disclosures Proctoring and honoraria for
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationTAVR: Current Valve Types. Patient Selection
TAVR: Current Valve Types. Patient Selection Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital
More informationTranscatheter Heart Valve Therapy
Edwards Lifesciences 2017 Investor Conference Transcatheter Heart Valve Therapy Larry L. Wood Corporate Vice President, Transcatheter Heart Valves Leader in ~$3B Global Transcatheter Heart Valves Primary
More informationPVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?
Joint Meeting 1 Aortic and Mitral Club Chairpersons: S.Adamopoulos, M. Vavuranakis, L. Michalis, P. Nihoyannopoulos PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationParavalvular Regurgitation is a Risk Factor Following TAVI
Paravalvular Regurgitation is a Risk Factor Following TAVI Philippe Pibarot, DVM, PhD, FACC, FESC, FASE Canada Research Chair in Valvular Heart Disease INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE
More informationSurgical aortic valve replacement (SAVR)
DAVID L. BROWN, MD The Heart Hospital Baylor Plano, Baylor Scott & White Health, Plano, TX Expanding indications for TAVR: The preferred procedure in intermediate-risk patients? ABSTRACT Transcatheter
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 2/2019 Origination: 2/2012 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationOptimal Imaging Technique Prior to TAVI -Echocardiography-
2014 KSC meeting Optimal Imaging Technique Prior to TAVI -Echocardiography- Geu-Ru Hong, M.D. Ph D Associate Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University
More informationNY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update
NY STATE NPA 33 rd Annual Conference TAVR & Structural Heart Update October 21, 2017 Rose Hansen DNP Structural Heart Coordinator Gates Vascular Institute, Buffalo NY TAVR Update: Objectives 1. Understand
More informationΕπεμβατική Καρδιολογία πέραν της Στεφανιαίας Νόσου Το παρόν και το μέλλον. Εμμανουήλ Βαβουρανάκης Καθηγητής Καρδιολογίας ΕΚΠΑ Δ/της Γ ΠΚΚ
Επεμβατική Καρδιολογία πέραν της Στεφανιαίας Νόσου Το παρόν και το μέλλον Εμμανουήλ Βαβουρανάκης Καθηγητής Καρδιολογίας ΕΚΠΑ Δ/της Γ ΠΚΚ CONFLICT OF INTEREST PROCTOR MEDTRONIC CORE VALVE ΔΙΑΚΑΘΕΤΗΡΙΑΚΗ
More informationStrokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center
Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationTranscatheter aortic valve replacement is considered investigational for all other indications.
Medical Policy Original Policy Date: March 30, 2012 Effective Date: July 1, 2018 Section: 7.0 Surgery Page: Page 1 of 33 Policy Statement Transcatheter aortic valve replacement with an U.S. Food and Drug
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationDisclosures. Overview. Surgical and TranscatheterAortic Valve Replacement: An Update on a Disruptive Technology 8/31/2016
Surgical and TranscatheterAortic Valve Replacement: An Update on a Disruptive Technology Ryan C. Shelstad, MD Cardiothoracic Surgery Bryan Heart Disclosures None relevant to the presentation Overview Background
More informationTAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
More information